An Outer Membrane Protein Preparation as a Vaccine against Pseudomonas aeruginosa Infection

Journal of Microbiology and Biotechnology

Volumn 7, Issue 2, 1997, Pages 144-150

  Park, Wan Je ^a   Cho, Yang Je ^a   Ahn, Dong Ho ^a   Jung, Sang Bo ^a   Lee, Na Gyong ^a   Kim, Hyun Su ^a   Hahm, Kyung Soo ^b   Kim, Yu Sam ^c  

^a CJ Corporation   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Outer membrane proteins; P. aeruginosa; Vaccine preparation

Indexed keywords

EID: 0006752672     PISSN: 10177825     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Baek, N. J., D. H. Kim, D. E. Lee, Y. Sunwoo, H. M. Han, S. T. Chung, P. S. Kim, and H. S. Kim. 1994. Antigenicity of CFC-101 (Pseudomonas vaccine) in guinea pigs and mice. J. Appl. Pharmacol. 2: 331-335.
2. Chang, W. H., M. S. Choi. W. H. Rhee, and J. S. Suk. 1982. Experimental study on effect of polyvalent Pseudomonas vaccine against Pseudomonas infection. Seoul J. Med. 23: 436-442.
3. Cho, H. J., J. H. Kim, D. H. Cho, D. H. Kim, K. H. Park, and H. S. Kim. 1994. Subacute toxicity study of CFC-101, Pseudomonas vaccine, in rats. Kor. J. Toxicol. 10: 261-271.
4. Cripps, A. W., M. L. Dunkley, and R. L. Clancy. 1994. Mucosal and systemic immunizations with killed Pseu- domonas aeruginosa protect against acute respiratory infection in rats. Infect. Immun. 62: 1427-1436.
5. Cryz, S. J., J. C. Sadoff, E. Fürer, and R. Germanier. 1986. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J. Infect. Dis. 154: 682-688.
6. Gilleland, H. E., L. B. Gilleland, and M. R. Fowler. 1993. Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model. J. Med. Microbiol. 38: 79-86.
7. Griffith, S. J., R. K. Nathan, R. K. Selander, W. Chamberlin, S. Gordon, S. Kabins, and R. A. Weinstein. 1989. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital. J. Infect. Dis. 160: 1030-1036.
8. Hancock, R. E. W. 1986. Intrinsic antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemotherapy. 18: 653-656.
9. Høiby, N. and O. Schiotz. 1981. Immune complex mediated tissue damage in the lungs of CF patients with chronic Pseudomonas aeruginosa infection., p. 147-157. In W. Warwick (ed.), 1000 years of cystic fibrosis. University of Minnesota Press, Minneapolis.
10. Jeong, S. M., J. H. Kim, C. W. Park, J. H. Kim, K. H. Park, and H. S. Kim. 1994. Acute toxicity of CFC-101, Pseudomonas vaccine, in rats and mice. Kor. J. Toxicol., 2: 255-260.
11. Kim, Y. G., J. H. Kim, W. J Park, D. H. Ahn, K. H. Hong, H. S. Kim, Y. S. Kim, and K. S. Hahm. 1994. Protective effect of CFC-101, a Pseudomonas vaccine, in mice. J. Appl. Pharmacol. 2: 322-325.
12. Kim, H. S., N. J. Baek, O. H. Kim, K. W. Ha, H. Y. Oh, E. S. Han, O. S. Heo, and W. J. Park. 1995. Mutagenicity tests on Pseudomonas vaccine (CFC-101). Environ. Mutagens Carcinogens 15: 51-55.
13. Korvick, J. A., J. W. Marsh, T. E. Starzl, and V. L. Yu. 1991. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem. Surgery 109: 62-68.
14. Masuyoshi, S., S. Mitsuhashi, M. Inoue, M. Hiraoka, and H. Matsui. 1991. In vitro and in vivo antibacterial activity and β-lactamase stability of cefepime, a new parenteral ccphalosporin. Chemotherapy 39: 1-14.
15. McManus, A. T., A. D. Mason, Jr., W. F. McManus, and B. A. Pruitt, Jr. 1985. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur. J. Clin. Microbiol. 4: 219-223.
16. Park, W. J., Y. J. Cho, Y. G. Kim, J. H. Kim, K. H. Park, Y. S. Kim, and K. S. Hahm. 1994. Active and passive protective effect of CFC-101 (Pseudomonas vaccine) in mice. J. Appl. Pharmcol. 2: 326-330.
17. Park, W. J., Y. H. Kim, S. M. Jeong, K. H. Park, H. S. Kim, Y. S. Kim, K. S. Hahm, P. L. Munt, and D. R. Algate. 1996. General pharmacology of a Pseudomonas vaccine prepared from outer-membrane fractions of Pseudomonas aeruginosa. Drug Res. 46: 1001-1006.
18. Pruitt, Jr., B. A., M. C. Colonel, and A. T. McManus. 1984. Opportunistic infections in severely burned patients. Am. J. Med. 30: 146-154.
19. von Specht, B-U, H. C. Lucking, B. Blum, A. Schmitt, K. D. Hungerer, and H. Domdey. 1996. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. Vaccine 14: 1111-1117.
20. Sawada, S., M. Suzuki, T. Kawamura, S. Fujinaga, Y. Masuho, and K. Tomibe. 1984. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharide and outer membrane proteins. J. Infect. Dis. 150: 570-576.
21. Stanislavsky, E. S., S. S. Balayan, A. I. Sergienko, T. A. Makarenko, L. S. Edvabnaya, M. A. Krohina, and V. M. Rusanov. 1991. Clinico-immunological trials of Pseudomonas aeruginosa vaccine. Vaccine 9: 491-494.
22. Stanislavsky, E. S., L. S. Edvabnaya, O. A. Bandman, V. F. Boolk, M. I. Zhvanetskaya, and A. K. Vargina. 1989. Experimental studies on the protective efficacy of a Pseudomonas aeruginosa vaccine. Vaccine 7: 562-566.